Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last ...
Bristol Myers Squibb (BMY) closed the most recent trading day at $60.18, moving +0.6% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.78%.
PRINCETON, N.J., March 03, 2025--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62 ...
Bristol-Myers Squibb has shown exceptional success in addressing challenges directly related to the introduction of generic versions of Revlimid and Sprycel. So, the gem in its oncology franchise ...
Bristol Myers Squibb stock (NYSE: BMY) has gained 7% this year, outperforming the S&P 500 which has declined 1%. BMS’s strong Q4 performance has helped drive its positive momentum. While markets ...
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company.
The collaboration has already yielded strong results, including the in-licensing of EVT8683 (now BMS-986419) by Bristol Myers Squibb in September 2021. In March 2023, the companies reaffirmed their ...
Bristol-Myers Squibb was founded in 1858 and has grown to be one of today's leading global pharmaceutical companies. For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover ...
2d
Zacks Investment Research on MSNBristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key FactsThe most recent trading session ended with Bristol Myers Squibb (BMY) standing at $60.28, reflecting a +0.79% shift from the previouse trading day's closing. The stock outpaced the S&P 500's daily ...
March 11 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab will acquire 2seventy bio (TSVT.O), opens new tab for about $286 million in cash, sending the cancer cell therapy maker's shares up ...
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of $118 billion, finds itself at a critical juncture as it navigates a complex landscape of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results